- Home
- PDM vs TRVI Comparison
PDM vs TRVI Comparison
Compare PDM & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDM
- TRVI
- Stock Information
- Founded
- PDM 1997
- TRVI 2011
- Country
- PDM United States
- TRVI United States
- Employees
- PDM N/A
- TRVI N/A
- Industry
- PDM Building operators
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- PDM Real Estate
- TRVI Health Care
- Exchange
- PDM Nasdaq
- TRVI Nasdaq
- Market Cap
- PDM 1.1B
- TRVI 1.1B
- IPO Year
- PDM N/A
- TRVI 2019
- Fundamental
- Price
- PDM $8.18
- TRVI $10.37
- Analyst Decision
- PDM Buy
- TRVI Strong Buy
- Analyst Count
- PDM 5
- TRVI 9
- Target Price
- PDM $9.40
- TRVI $20.72
- AVG Volume (30 Days)
- PDM 847.3K
- TRVI 1.7M
- Earning Date
- PDM 10-27-2025
- TRVI 11-05-2025
- Dividend Yield
- PDM 3.06%
- TRVI N/A
- EPS Growth
- PDM N/A
- TRVI N/A
- EPS
- PDM N/A
- TRVI N/A
- Revenue
- PDM $565,502,000.00
- TRVI N/A
- Revenue This Year
- PDM N/A
- TRVI N/A
- Revenue Next Year
- PDM N/A
- TRVI N/A
- P/E Ratio
- PDM N/A
- TRVI N/A
- Revenue Growth
- PDM N/A
- TRVI N/A
- 52 Week Low
- PDM $5.46
- TRVI $2.36
- 52 Week High
- PDM $11.12
- TRVI $11.11
- Technical
- Relative Strength Index (RSI)
- PDM 40.42
- TRVI 68.47
- Support Level
- PDM $7.99
- TRVI $9.29
- Resistance Level
- PDM $8.40
- TRVI $11.11
- Average True Range (ATR)
- PDM 0.21
- TRVI 0.56
- MACD
- PDM -0.09
- TRVI 0.06
- Stochastic Oscillator
- PDM 22.48
- TRVI 75.73
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.